Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD

1.48  +0.82 (+125.27%)

After market: 1.58 +0.1 (+6.76%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XLO. XLO was compared to 572 industry peers in the Biotechnology industry. XLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XLO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XLO had negative earnings in the past year.
In the past year XLO has reported a negative cash flow from operations.
In the past 5 years XLO always reported negative net income.
XLO had a negative operating cash flow in each of the past 5 years.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

XLO's Return On Assets of -84.12% is on the low side compared to the rest of the industry. XLO is outperformed by 70.09% of its industry peers.
The Return On Equity of XLO (-299.43%) is worse than 75.22% of its industry peers.
Industry RankSector Rank
ROA -84.12%
ROE -299.43%
ROIC N/A
ROA(3y)-74.51%
ROA(5y)-80.65%
ROE(3y)-110.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 600 800 1K

1.3 Margins

XLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for XLO has been increased compared to 1 year ago.
XLO has a better debt/assets ratio than last year.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

XLO has an Altman-Z score of -8.98. This is a bad value and indicates that XLO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.98, XLO is not doing good in the industry: 72.39% of the companies in the same industry are doing better.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.98
ROIC/WACCN/A
WACCN/A
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

XLO has a Current Ratio of 1.67. This is a normal value and indicates that XLO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of XLO (1.67) is worse than 80.89% of its industry peers.
A Quick Ratio of 1.67 indicates that XLO should not have too much problems paying its short term obligations.
XLO's Quick ratio of 1.67 is on the low side compared to the rest of the industry. XLO is outperformed by 79.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.67
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.89% over the past year.
EPS 1Y (TTM)41.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.79% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.58%
EPS Next 2Y34.75%
EPS Next 3Y22.45%
EPS Next 5Y12.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLO. In the last year negative earnings were reported.
Also next year XLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

XLO's earnings are expected to grow with 22.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.75%
EPS Next 3Y22.45%

More info and screens

0

5. Dividend

5.1 Amount

XLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (2/12/2025, 5:02:58 PM)

After market: 1.58 +0.1 (+6.76%)

1.48

+0.82 (+125.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners30.22%
Inst Owner Change-93.93%
Ins Owners0.46%
Ins Owner Change13.55%
Market Cap67.67M
Analysts80
Price Target4.59 (210.14%)
Short Float %0.81%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.19%
Min EPS beat(2)-3.31%
Max EPS beat(2)11.7%
EPS beat(4)2
Avg EPS beat(4)-112.17%
Min EPS beat(4)-458.06%
Max EPS beat(4)11.7%
EPS beat(8)5
Avg EPS beat(8)-49.95%
EPS beat(12)8
Avg EPS beat(12)-30.11%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-62.16%
Min Revenue beat(2)-92.22%
Max Revenue beat(2)-32.1%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)-18.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.99%
EPS NY rev (1m)0%
EPS NY rev (3m)9.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)24.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.65
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB 3.23
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.1
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.12%
ROE -299.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.51%
ROA(5y)-80.65%
ROE(3y)-110.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.51%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.67
Altman-Z -8.98
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)66.66%
Cap/Depr(5y)140.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.93%
EPS Next Y58.58%
EPS Next 2Y34.75%
EPS Next 3Y22.45%
EPS Next 5Y12.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.64%
EBIT Next 3Y1.99%
EBIT Next 5Y-9.94%
FCF growth 1Y76.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.36%
OCF growth 3YN/A
OCF growth 5YN/A